RhAPPcast

RhAPPcast

Por: Rheumatology Advanced Practice Providers (RhAPP)
This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs). 
 
Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases. 
138 episodios disponibles

Latest episodes of the podcast RhAPPcast

Mostrando página 5 de 7

Medication Review: What Is the Efficacy of Ixekizumab Across the GRAPPA and EULAR Domains? 16/12/2024
Medication Review: What Is the Safety Profile of Guselkumab in PsO and PsA? 11/12/2024
FAQ: How Does Axial PsA Differ From AS Clinically, Genetically, and Radiographically? 04/12/2024
Journal Club Review: 6-Month Guselkumab Effectiveness in PsA (Real-World CorEvitas Data) 20/11/2024
RhAPPcast: Navigating the Complexities: IL-17 Inhibitors and IBD Risk 13/11/2024
FAQ: Why is Binding CD64+ Important When Discussing IL23 Directed Therapy 06/11/2024
Journal Club Review: Upadacitinib Safety & Efficacy in Pediatric JIA (Phase-1 Interim Data) 04/11/2024
RhAPPcast: Lost Time: The Impact of Delaying Optimal Therapy in RA & SpA Patients Without Disease Control 01/11/2024
Journal Club Review: 5-Year Data on Switching Upadacitinib & Adalimumab in RA 30/10/2024
FAQ: Definition of Remission in Rheumatoid Arthritis & Likelihood with Advanced Therapies 25/10/2024
Medication Review: How is Guselkumab dosed in PsO, PsA, and IBD 23/10/2024
RhAPPcast: Navigating Remission in Rheumatoid Arthritis: Approaches, Advances, Impact, and Insights 18/10/2024
FAQ: Variability in JAK Inhibition Specificity & Its Clinical Implications 16/10/2024
RhAPPcast: CD64+ Binding Description, Relevance, and Potential Clinical Implications 16/10/2024
FAQ: What Is the Difference Between Biosimilars and Generics? 14/10/2024
FAQ: What Is the ORAL Surveillance Study and How Can It Be Applied to Clinical Practice? 11/10/2024
FAQ: What is the Safety Profile of Ixekizumab in PsA and axSpa 09/10/2024
Medication Review: What Is the Safety Profile of Upadacitinib Across Indications? 07/10/2024
FAQ: Provide Immunologic Rationale For IL23 Directed Therapy in PsA, PsO, and IBD. 02/10/2024
RhAPPcast: Biosimilars and The Patient Perspective 30/09/2024
« Primera ‹ Anterior 1 ... 3 4 5 6 7 Siguiente › Última »
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA